We are live on ! Find out more
CYT

Cyteir Therapeutics, Inc. Common Stock
CYT

Delisted

CYT was delisted on the 15th of March, 2024.

Back to rankings

37 hedge funds and large institutions have $34.6M invested in Cyteir Therapeutics, Inc. Common Stock in 2022 Q3 according to their latest regulatory filings, with 2 funds opening new positions, 11 increasing their positions, 14 reducing their positions, and 10 closing their positions.

New
Increased
Maintained
Reduced
Closed

0% more funds holding in top 10

Funds holding in top 10: 1 → 1 (0)

18% less funds holding

Funds holding: 45 → 37 (-8)

21% less repeat investments, than reductions

Existing positions increased: 11 | Existing positions reduced: 14

39% less capital invested

Capital invested by funds: $56.8M → $34.6M (-$22.2M)

80% less first-time investments, than exits

New positions opened: 2 | Existing positions closed: 10

Holders
37
Holders Change
-8
Holders Change %
-17.78%
% of All Funds
0.64%
Holding in Top 10
1
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.02%
New
2
Increased
11
Reduced
14
Closed
10
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
CCM
CAAS Capital Management
New York
+$1.4M
2
BCM
Bridgeway Capital Management
Texas
+$130K
3
NM
Newtyn Management
New York
+$125K
4
Geode Capital Management
Geode Capital Management
Massachusetts
+$94K
5
CC
Cannell Capital
Wyoming
+$41.2K

Top Sellers

Rank Fund Capital Flow
1
NHAS
Novo Holdings A/S
Denmark
-$2.35M
2
Fidelity Investments
Fidelity Investments
Massachusetts
-$1.01M
3
Morgan Stanley
Morgan Stanley
New York
-$381K
4
Renaissance Technologies
Renaissance Technologies
New York
-$210K
5
D.E. Shaw & Co
D.E. Shaw & Co
New York
-$175K
Name Holding Trade Value Shares
Change 		Change in
Stake
NHAS
1
Novo Holdings A/S
Denmark
$7.57M -$2.35M -900,000 -19%
Fidelity Investments
2
Fidelity Investments
Massachusetts
$6.69M -$1.01M -386,231 -10%
BBA
3
Baker Bros. Advisors
New York
$5.08M – – –
OMC
4
OUP Management Company
Pennsylvania
$4.74M -$13K -5,000 -0.2%
APM
5
Avidity Partners Management
Texas
$3.47M -$114K -43,800 -2%
CCM
6
CAAS Capital Management
New York
$1.27M +$1.4M +536,938 +672%
NM
7
Newtyn Management
New York
$1.26M +$125K +47,864 +8%
Vanguard Group
8
Vanguard Group
Pennsylvania
$1.12M -$70.7K -27,106 -4%
LCM
9
Laurion Capital Management
New York
$690K – – –
Renaissance Technologies
10
Renaissance Technologies
New York
$512K -$210K -80,521 -23%
BlackRock
11
BlackRock
New York
$376K -$12K -4,592 -2%
RC
12
RBF Capital
California
$293K – – –
EWM
13
Evercore Wealth Management
New York
$282K – – –
BCM
14
Bridgeway Capital Management
Texas
$230K +$130K +50,000 +72%
Millennium Management
15
Millennium Management
New York
$229K -$20.6K -7,915 -6%
Geode Capital Management
16
Geode Capital Management
Massachusetts
$218K +$94K +36,041 +46%
Morgan Stanley
17
Morgan Stanley
New York
$133K -$381K -146,039 -68%
UBS Group
18
UBS Group
Switzerland
$67K +$14.3K +5,473 +19%
Two Sigma Advisers
19
Two Sigma Advisers
New York
$54K +$15.4K +5,900 +26%
State Street
20
State Street
Massachusetts
$46K – – –
Bank of America
21
Bank of America
North Carolina
$40K -$14K -5,361 -20%
CC
22
Cannell Capital
Wyoming
$38K +$41.2K +15,793 +406%
ACM
23
ACT Capital Management
Pennsylvania
$29K – – –
Two Sigma Investments
24
Two Sigma Investments
New York
$25K -$29.4K -11,269 -46%
Northern Trust
25
Northern Trust
Illinois
$25K – – –
1
2

CYT Hedge Fund Activity: Q3 2022 in Review

37 of the 5,805 institutional investors tracked by Wall St. Rank reported a position in Cyteir Therapeutics, Inc. Common Stock (CYT) for Q3 2022, worth a combined $34.6M — down 39% from $56.8M a quarter earlier.

Sellers outnumbered buyers: 10 funds closed out of CYT and 2 opened new positions — a net loss of 8 holders — while 14 trimmed existing stakes and 11 added.

The largest buyer was CAAS Capital Management, adding an estimated $1.4M. The largest seller was Novo Holdings A/S, cutting an estimated $2.35M.

  • 37 institutional investors held Cyteir Therapeutics, Inc. Common Stock (CYT) as of Q3 2022, down from 45 in Q2 2022.
  • Funds reported $34.6M of Cyteir Therapeutics, Inc. Common Stock stock for Q3 2022, down 39% quarter-over-quarter.
  • 2 funds opened new Cyteir Therapeutics, Inc. Common Stock positions in Q3 2022 and 10 closed out, a net change of -8 holders.
  • The largest Cyteir Therapeutics, Inc. Common Stock buyer in Q3 2022 was CAAS Capital Management, an estimated $1.4M added.
  • The largest Cyteir Therapeutics, Inc. Common Stock seller in Q3 2022 was Novo Holdings A/S, an estimated $2.35M sold.

Based on aggregated 13F filings for Q3 2022.